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Natural killer (NK) cells are large granular lymphocytes (LGL), that express
cytolytic activity in vitro against varioustumor cells, virally infected cells, and some
microorganisms (1-3) . They do not productively rearrange TCR genes (4-6), do
not express CD3 (7), and are capable of lysing target cells without major histocom-
patibility restriction (8, 9) or previous antigen sensitization (10, 11) . Extensive evi-
dence indicates thatNK cells are responsible forrejection of certain implanted syn-
geneic tumors and inhibition of certain experimental tumor metastasis (12-15) .
We have recently described an IgGlk mAb, termed 3.2.3, that recognizes a 60-kD
disulfide-linked dimercomposed of two 30-kD subunits expressed exclusivelyon fresh
and IL-2-activated rat LGL/NK cells and polymorphonuclear cells(PMN) (16) .mAb
3.2.3 can enhance cytolytic activity of LGL/NK cells against certain FcR' tumor
target cells, by reverse antibody-dependent cellular cytotoxicity (ADCC) and also
inducesthe releaseofBLTesterase from IL-2-activatedNK cells . These data suggest
that mAb 3.2 .3 recognizes a unique triggering structure present on fresh and IL-2-
activated NK cells .
In this study we investigated the in vivo effects of mAb 3 .2.3 in F344 . rats . Our
results show that intraperitoneal treatment of rats withmAb3.2 .3 for 1-3d cancom-
pletelyand selectively eliminateNKandADCC activity as well as LGL in the spleen
and peripheral blood . Depletion of NK activity markedly decreased the survival of
F344 rats injected intravenously with MADB106 mammary adenocarcinoma cells,
confirming the important role NK cells play in controlling the metastasic spread
of certain tumors .
Volume 171 January 1990 197-210
Materials and Methods
Animals.
￿
Male Fischer344 rats (75-100 g) were purchased from Taconic Farms, Inc. (Ger-
mantown, NY) andwere housed ina specific pathogen-free animal facility at the Pittsburgh
Cancer Institute for at least 10 d before use .
This work was supported in part by grants CH416 from the American Cancer Society, CA-47087 from
the National Institutes of Health, and by a grant from the Ank van Vlissingen Foundation.
Address correspondence to Dr. John C. Hiserodt, Pittsburgh Cancer Institute, 3343 Forbes Avenue,
Pittsburgh, PA 15213 .
1 Abbreviations used in thispaper. ADCC, antibody-dependent cellular cytotoxicity; LGL, large granular
lymphocyte ; PMN, polymorphonuclear cell; RPE, Rphycoerythrin.
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Tumor Cells.
￿
The lysis ofthe NK-sensitive Moloney virus-induced mouse T cell lymphoma
YAC-1 was used as an indicator of NK activity (17). The NK-resistant mastocytoma P815
(18) was used as the target in ADCC assays. The F344 mammary adenocarcinoma MADB106
(15) was injected into F344 rats for tumor survival experiments. All tumor cell lines were
grown in RPMI 1640, 5% FCS, penicillin/streptomycin (complete medium, CM), and sub-
cultured two to three times per week.
Preparation ofLymphoid Cells.
￿
Spleens were aseptically removed and single cell suspensions
were prepared in RPMI 1640 with 5% FCS. Peripheral blood was obtained by cardiac punc-
ture using heparinized syringes. Mononuclear cells were obtained after centrifugation on
Ficoll-Hypaque gradients (density 1.077) at 300g (for spleen cells) or 400 g (for PBMC) for
20 min. All lymphoid cells were washed twice in RPMI 1640 with 5% FCS and counted
before use. Viabilities were routinely >97% by trypan blue exclusion. In some experiments,
spleen mononuclear cells were passed over nylon-wool columns to remove monocytes/macro-
phages and B cells (19).
Cytotoxicity Assay.
￿
Cytotoxicity was measured in a standard 4-h "Cr-release assay using
96-well, round-bottomed microplates (Costar, Cambridge; MA). The target cells were la-
beled with 100 1ACi of Nat"CrO4 per 2 x 106 cells, washed, and seeded at 5 x 103 cells/well.
Suspensions of effector cells were then added to triplicate wells to give various E/T ratios
in a final volume of 200 p.l. After an incubation at 37°C for 4 h, 100 ul of supernatant was
removed from each well and was counted in a gamma counter to determine experimental
release. Spontaneous release was obtained from wells receiving target cells and medium only,
and total release was obtained from wells receiving 1°Io Triton X-100. Percent cytotoxicity
was calculated by the following formula: Percent cytotoxicity = 100 x [(experimental release-
spontaneous release)/(total release-spontaneous release)]. Assays of ADCC were performed
as described above, with additional pretreatment of the P815 targets with 10 pl of rat anti-
P815 serum for 30 min .
Proliferative Response to Con A.
￿
Spleen cells from control or NK-depleted rats were cultured
in triplicate in 0.2 ml complete medium (CM) at a concentration of 1 x 105 cells/well in
the presence or absence of Con A (10 lag/ml) in 96-well flat-bottomed microplates. After 72
h of incubation at 37°C in 5% 002/95% air, the cells were pulsed with 1 wCi of [3H]thymi-
dine (New England Nuclear, Boston, MA) for 12 h and subsequently harvested with a MASH
II harvester for measurement of their radioactivity in a scintillation counter.
Antibodies.
￿
The following anti-rat mAbs were used: OX8 (CD8), OX19 (CD5), OX34
(CD2), OX41 (macrophages, dendritic cells), and W3/25 (CD4) were all purchased from
Bioproducts for Science (Indianapolis, IN). ART 18 (which identifies the low affinity IL-2
receptor CD25) was a gift from T Diamantstein (Freie Universitat Berlin, Berlin, FRG).
R73 (which identifies the rat TCR-ala) was kindly provided by T. Hunig (Ludwig Max-
imilians University, Munich, FRG) (20). Rabbit anti-asialo GM, serum was obtained from
WAKO Chemical (Dallas, TX). mAb 3.2.3 was produced as previously described (16). IgG
antibody was purified from ascites fluid by amity chromatography over protein A-Sepharose
and was shown to be 98% pure by SDS-PAGE analysis. When used for FAGS analysis, directly
labeled FITC-F(ab')2 fragments were used. For fluorescence staining each of the various an-
tibodies was used at an optimal dilution based on preliminary dose-response titrations. All
second-step antibodies were RPE- or FITC-labeled F(ab')2 fragments of goat antibody
against the primary antibody (Cappel Laboratories, Malvern, PA).
Flow Cytometry.
￿
For surface marker analysis, 2 .5 x 105 cells in 0.1 ml of staining buffer
(0.1% sodium azide and 2% FCS in PBS, pH 7.3) were incubated with various antibodies
for 30 min at 4°C. The cells were washed twice with staining buffer and resuspended in FITC-
labeled second antibody. After 30 min at 4°C, the cells were again washed twice with staining
buffer, resuspended in 1% paraformaldehyde, and analyzed for fluorescence staining on a
FACStar flow cytometer (Becton Dickinson & Co., Mountain View, CA).
Evaluation of Cell Morphology.
￿
Morphologic differentials were determined microscopically
from Giemsa-stained cytocentrifuge slides or Giemsa/Wright-stained blood smears. At least
200 cells were examined by two independent observers for each slide.
Treatment ofRats.
￿
F344 rats were injected intraperitoneally with varying doses of affinity-
purified mAb 3 .2.3 or mAb 3.2 .3 ascites (containing a total protein concentration of 10 mg/mlVAN DEN BRINK ET AL.
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of which 3 mg/ml was shown to be monoclonal IgGl) in 1 ml of HBSS once a day for 1-3
d. Control animals received injections of ascites fluid containing irrelevant IgGl antibody
or purified irrelevant IgG1 antibody each diluted in HBSS. In tumor challenge experiments,
animals were treated with one dose of 100 1tl of mAb 3.2 .3 ascites intraperitoneally and 3
d later were injected with 1.5 x 106 MADB106 cells intravenously or 5 x 106 MADB106 cells
subcutaneously. In one experiment animals were pretreated for three consecutive days with
50 pg/ml affinity-purified 3.2.3 intraperitoneally and 1 d later were injected intravenously
with 0.5 x 106 MADB106 cells. In vivo growth of subcutaneous tumors was measured over
a period of 30 d with Vernier calipers measuring 2 diameters at right angles.
Statistics.
￿
For survival experiments, Kaplan-Meer curves were drawn and the differences
in survival between the various groups was assessed using the generalized Savage (Mantel-
Cox) log-rank test. For statistical analysis ofblooddifferential counts the Mann-Whitney and
the Student's t-test were used. All other statistical analysis was performed using the Student's
t-test.
Results
Effect of In Vivo Treatment of F344 Rats with mAb 3.2.3 on NK Activity and ADCC of
Fresh Spleen Cells andPBMC. We treated F344 rats with 100 141 of mAb 3.2.3 ascites
intraperitoneally once a day for 3 d. 1 d later (on day 4) both NK and ADCC activi-
ties of PBMC and spleen cells were determined. Table I shows that NK and ADCC
activity of fresh PBMC and spleen cells were virtually eliminated after treatment
with mAb 3 .2 .3 . To study the dose dependence and kinetics of this effect, we treated
rats with various amounts of mAb and measured NK activity of fresh spleen cells
at different intervals after treatment. As shown in Fig. 1, treatment for 3 d with 100
p.l mAb 3.2.3 ascites once a day could completely eliminate NK activity for >10 d.
NK activity then returned to nearly control levels by day 19 . The depression in NK
activity was dose dependent as both the absolute level of depression as well as the
duration of depression were dependent on the quantity of ascites administered.
We also studied the effects of a single dose treatment with either 50 td or 100 pl
TABLE I
NK andADCC Activities of Fresh Spleen Cells and PBMCfrom
Untreated and 3.2.3-treated F344 Rats
Rats were treated for 3 d with 100 PI of mAb 3.2 .3 ascites or control ascites once a day i.p.
On day 4, mononuclear cells were obtained and tested for NK and ADCC activity in 4-h
5'Cr-release assays.
* Effector/target ratio.
t Effector/target ratio of 50:1.
S Mean percentages t SD of cytotoxicity from five rats in each group.
ADCC
(cytotoxicity vs. P815t)
NK-activity Without With
Cells
Treatment
of rats
(cytotoxicity
100:1*
vs. YAC-1)
50:1
anti-P815
serum
anti-P815
serum
Spleen cells Untreated 47 t 3S 35 1 2 3 t 2 18 1 3
Control ascites 52 1 8 42 1 7 4 1 0.5 17 1 3
3.2 .3 ascites 1 t 2 0 t 2 0 t 4 0 t 1
PBMC Untreated 22 1 4 20 1 3 0 t 0 18 1 2
Control ascites 20 1 3 16 1 2 1 t 1 16 1 1
3.2 .3 ascites 4 t 1 .5 4 t 2 0 t 0.5 1 t 1 .5200
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FIGURE 1 .
￿
NK activity in F344 rats
treatedwith varying doses ofmAb3.2 .3
ascites for 3 d (one injection/day, i.p.).
NK activity was determined as lytic ac-
tivity of fresh spleen cells from 3.2.3-
treated rats against YAC-1 targets at an
E/T ratio of 50 :1 and compared with
NK activityofcontrol rats treated with
irrelevant ascites . Each column repre-
sentsmean NK-activity oftwo rats ex-
pressed as percentage ofthemeanNK
activity oftwo control rats.NK activity
of control rats was 26 f 9% .
mAb 3.2.3 ascites and found that depletion ofNK activity could last up to 4 d after
a single treatment with 50 pl mAb and up to 11 d after a single treatment with 100
A.1 mAb (Fig . 2) .
To rule out that the NK depletion in vivo was caused by a nonspecific effect of
themAb 3.2.3 ascites fluid, we treated rats with different concentrations of affinity-
purified antibody. Fig. 3 shows that even treatment with a dose as low as 0.05 mg
ofaffinity-purified 3.2.3 IgGcouldcompletely deplete splenicNKandADCC activity .
Cell Surface Phenotype and Percentage ofLGL in Fresh Spleen Cells from 3.2.3-treated
Rats. The selective depletion of NK activity in 3 .2 .3-treated rats correlated with
an altered expression ofcell surfacemarkersassociated withNK cells . Table II shows
a decreased expression ofCD2 (present onT cells andNK cells), CD8 (present on
T cytotoxic/suppressor cells and NK cells), asialo GM, (present on NK cells and
subpopulations of macrophages and cytotoxic T cells), and 3.2.3 (present on NK
cells and PMN) . Moreover, the percentage ofLGL, as counted in Giemsa-stained
cytospin preparations, was decreased from 4.3 t 0 .9 in untreated rats to 0.4 t 0 .4
in 3.2.3 treated rats .
The low number (6%) of 3.2.3 + cells that were still present after 3.2.3 treatment
were found to express the3.2.3 antigen only dimly(Fig. 4) . Two-colorFRCS analysis
showed that half of these 3 .2.3(dim+) cells coexpressed CD5, indicating aT cell
origin . Spleen cells from normal rats also contain a subpopulation of CD5+/
3 .2.3(dim+) cells (-6%), and we found that these cells areCD8+ , CD2` and TCR-
a/a+ T cells that are not capable of lysing NK-sensitive targets or of ADCC even
after 5d ofculture with IL-2 (manuscript in preparation) . Interestingly, Fig . 5 also
shows a small subpopulation (3.0%) of CD5 -/3.2.3(dim+) cells, which is present
in spleen cells from 3.2 .3-treated rats, butnot in spleen cells from normal rats . Fur-
ther analysis of these CD5 -/3.2.3(dim+) cells in 3 .2 .3-depleted rats showed that
these cells are CD2+, CD8+ (N50%),CD4-, TCRa/j3- , and display less cytolytic
activity against NK-sensitive targets than CD5 -/3.2.3 (bright+) cells (data not
shown) . This suggests that these CD5-/3.2.3(dim+) cells, which were only foundVAN DEN BRINK ET AL .
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FIGURE 2 .
￿
NK and ADCC activity
in F344 rats treated with one dose of
50 or 100 )Al i.p . ofmAb 3.2 .3 ascites .
Each column represents mean splenic
NK activity (E/T ratio 50:1)orADCC
(E/T ratio 25:1) of two rats expressed
as percentages of the mean NK or
ADCC activity oftwo control rats. NK
activity of control rats was 23 t 7OJo
and ADCC was 21 t 6%.
in 3 .2.3-treated rats, could be either immature NK cells or functionally impaired
NK cells . Table II also shows that the total number ofT cells (0X19+ as well as
TCRa/f3+) was not affected by the treatment with 3.2.3 .
T Cell Function and Numbers ofPMN Are Not Affected by Treatment ofF344 Rats with
mAb 3.2.3 Ascites. Rats were treated for 3 d with 100 j,1 ofmAb 3.2.3 ascites once
a day. 1 d after treatment, spleen cells were cultured with 10 hg/ml Con A. After
72 h proliferation was determined in a 12-h (3H]thymidine incorporation assay.
Table III shows that T cell function, as measured by Con A stimulation in vitro,
was not affected by treatment with mAb 3.2.3 ascites in vivo.202
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TABLE II
Phenotype and Percentage of LGL in Fresh Spleen Cellsfrom
Untreated and 3.2.3-treated F344 Rats
FIGURE 3 .
￿
NK andADCC activity in F344
rats treated with varying doses of affinity-
purifiedmAb 3.2 .3 orpurified irrelevant IgG
for two consecutive days. SplenicNK activity
(E/T ratio 50:1) and ADCC (E/T ratio 50:1)
was determined 2 days later (day 4) . Each
column represents mean NK or ADCC ac-
tivity of two rats.
We also performed blood differential analysis on Giemsa-Wright-stained periph-
eral blood smears to determine if PMN, which express low levels of the antigen
identified by mAb 3.2.3, are affected by treatment with mAb 3.2.3 ascites in vivo.
Table IV shows that no significant differences in percentages or absolute numbers
ofPMNs, lymphocytes, or monocytes were noted after treatment with mAb 3.2.3 .
Also the percentage of immature PMNs with band-shaped nuclei wasnot changed .
Surface markers
OX19
W3/25
OX8
OX34
R73
ART 18
OX41
Asialo GMI
3 .2.3 (bright +)
3 .2 .3 (dim +)
LGLT
￿
4 .3 t 0 .9 (3-5)
￿
0.4 t 0.4 (0-0 .8)
Rats were treated with a single injection of 100 Al of 3.2 .3 ascites or irrelevant ascites . 3 d
later, nylon wool-nonadherent spleen cells were analyzed for the expression of cell surface
markers by flow cytometric analysis and for the percentage of LGL in Giemsa-stained cytospin
preparations .
" Mean percentage t SD from four rats in each group .
T Mean percentage t SD from four rats in each group . Numbers in parentheses are ranges .
CD equivalent
Percentage of positive
spleen cells from :
Control rats 3.2.3-Treated rats
CD5 81 t 1' 84 t 2
CD4 41 f 1 40 f 1
CD8 49 t 2 41 t 1
CD2 89 t 3 82 ± 1
TCR-a//3 75 t 2 74 t 3
CD25 4 f 2 4 t 1
Macrophages 3 t 2 3 t 2
NK cells, subpopulations of 74 t 5 63 ± 2
macrophages, and cyto-
toxic T cells
NK cells 12 t 1 0 t 0
PMN and a subset of 6 t 2 6 t 1
CD8' T cellsVAN DEN BRINK ET AL.
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FIGURE 5.
￿
Survival of 3.2.3-
treated or control IgG-treated
F344 rats after injection ofMAD-
B106 cells ix. (A) F344 rats were
injected with 100 pl of mAb
3.2.3 ascites or irrelevant ascites
in HBSS i.p. and received 1.5
x 106 tumor cells 3 d later.
Groups consisted ofsix animals
in the 3.2.3-treated and eight
animals in the control group.
Survival after tumorinoculation
is shown with Kaplan-Meier
curves. Statistical analysis with
the Savage (Mantel Cox) log-
rank test showed a significant dif-
ference in survival (p < 0.0005).
Results are representative oftwo
experiments with similar out-
come. (B) F344 rats were pre-
treated for three consecutive
days with 0.05 mg/ml affinity-
purified 3.2.3 IgG or control
IgG and received 0.5 x 106
tumor cells 1 d later. Groups
consisted of six animals in both
groups and the survival differed
significantly (Savage (Mantel
Cox) log-rank test; p < 0.005).
TABLE III
Proliferative Response to Con A of Fresh Spleen Cells
from 3.2.3-treated F344 Rats
F344 rats were treated with 100 Al of3 .2.3 ascites or irrelevant ascites in 1 ml
HBSS for three consecutive days. On day 4, spleens were removed and cells
were cultured in triplicate at a concentration of 1 x 105 cells/well with or
without 10,ag/ml Con A. After 72 h, cells were pulsed with 1 ACi of [3H]thy-
midine for 12 h and subsequently harvested.
' Two rats/group.
Mean t SD of [3H]thymidine uptake (cpm).
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3.2.3 treated rats
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PERCENT OF 50 1 _
SURVIVORS
1
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j
I
I
1
1
0
5
I
I
t
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100
1
=-t-
1
I
I
-= 3.2.3 treated rats
I
I
0
t
PERCENT OF 50
I
SURVIVORS
1
1
25
1
1
t
10 20 30 40 50
DAYS
Exp. Group' Without ConA With ConA
1 Control 3,404 t 2,0571 113,873 t 11,222
3.2.3-Treated 2,558 t 1,836 124,122 t 19,566
2 Control 3,708 t 1,540 119,209 t 11,159
3.2 .3-Treated 3,530 f 1,554 163,859 * 28,24050 n
40 -i
0
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TABLE IV
Differential Cell Counts on Peripheral Bloodfrom 3.2.3-treated F344 Rats
Polymorphonuclear cells
205
Rats were treated with 0.1 ml of mAb 3 .2.3 ascites or irrelevant ascites (control) in 1 ml HBSS i.p. for
three consecutive days (once a day). 1 day later (day 4) peripheral blood smears were prepared, Giemsa/
Wright-stained, and analyzed for differential cell counts. No significant differences were found by statisti-
cal analysis with the Student's t-test or the Mann-Whitney test.
Mean values t SE of six rats in each group.
t Mean percentage t SE and absolute number t SE ( x 10- 3/ml) in brackets.
EffectsofTreatmentwith mAb 3.2.3 on Subcutaneous TumorGrowth or Survival afterIntra-
venous Injection ofMADB106 Tumor Cells in F344 Rats. We studied the effects of NK
depletion with mAb 3.2 .3 on tumor growth and survival of the mammary adenocar-
cinoma MADB106 in F344 rats. Rats were treated with a single dose of 100 JA mAb
3.2 .3 ascites and injected with 1.5 x 106 tumor cells intravenously 3 d later. Fig.
5A shows the survival of3.2.3 treated or control rats after tumor injection depicted
as Kaplan-Meier curves. The 3.2 .3-treated group had a significantly shorter sur-
vival than the control group (Savage (Mantel Cox) log-rank test; p < 0.0005).
Similarresultswere obtained when animals were pretreated with 0.05 mg/ml affini-
ty-purified mAb 3.2 .3 and injected 1 d later with 0.5 x 106 MADB106 cells intra-
venously (Fig. 5 B). In contrast, when 5 x 106 MADB106 cells were injected sub-
cutaneously, no significant difference (p > 0.05) in tumor growth between the
3.2 .3-treated and control groups wasnoted at any time over a 30-d period (Figure 6).
CONTROL 3.2.3
TREATED
FIGURE 6. Subcutaneous
￿
tumor
growth in3.2.3 treated orcontrol (HBSS
treated) F344 rats after injection of5 x
106 MADB106 cells s.c. Each group
consisted ofeight animals. Growth of
s.c. tumors was measured over a 30-d
period and presented as tumor sizeon
day 17. Tumor sizes and means ofeach
group are depicted. Statistical analysis
using the Student's 1-test showed no
significant difference (p > 0.05) in s.c.
tumor growth between control and
3.2.3-treated animals.
Z
30
TUMOR
SIZE
(in mm)
20
10 -
Treatment
of rats
WBC
(x 10-3/ml) Neutrophils Eosinophils
Band-shaped
nuclei Lymphocytes Monocytes
Control IgG 9,895 t 744' 13 t 2.91 0.7 t 0.2 2.1 f 0.6 81 t 2.1 3.1 t 0.5
(1,501 t 416) (72 t 19) (223 t 68) (7,290 t 167) (323 t 75)
3.2.3 8,482 t 181 15 t 2.9 1 .2 t 0.2 2 .0 t 0.8 79 t 4.0 3 .1 t 0.7
(1,276 t 264) (106 t 18) (173 t 67) (6,666 t 312) (271 t 63)206
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Discussion
In this study we have shown that in vivo treatment ofrats with mAb 3.2.3, which
recognizes atriggeringstructurepresentonNKcells, cancompletely andselectively
eliminate NK and ADCC activities for >10d. The NK depletion in vivo with mAb
3.2.3 was highly selective as T cell function, percentages ofTcells, monocytes, or
PMNs were not affected. Moreover, this is the first study to demonstrate that selec-
tive depletion of LGL/NK cells in vivo also eliminates ADCC function in vitro.
Chambers et al. (16) previously reported that mAb 3.2.3 did not block NK ac-
tivity in vitro. The in vivo effects of mAb 3.2.3 are, therefore, most likely due to
physical removal of NK cells either by complement-mediated lysis, ADCC or se-
questration. The virtual absence of LGL in Giemsa-stained cytospin preparations,
as well as the absence of 3.2.3(bright+) cells in the blood or spleen, supports this
hypothesis. Barlozzari et al. (21) also found similar correlation between a decrease
in NK activity and a decrease in the numberofLGL aftertreatmentwith anti-asialo
GMi antibody.
In concordance withthe depletion ofNK/ADCC function and LGL, we alsofound
quantitatively decreased expression ofNK-associated surface markers (CD2, CD8,
asialo GMI, and 3.2.3) on spleen cells from 3.2.3-treated rats but no changes in sur-
face markers not expressed on NK cells (CD5, CD4, OX41, and TCRado). The
remaining3.2.3(dim+)cellsin3.2.3-treated ratswere foundbytwo-colorFAGSanalysis
to contain CD5+ as well as CD5- cells. The CD5+ cells were unequivocally shown
to be T cells as they also expressed the TCRcad3. The CD5-/3.2.3(dim+) cells
present in 3.2.3-treated rats were found to coexpress CD2 and CD8 (N50%) but
not CD5, CD4, orTCRa/(3. These cells showed less cytotoxicityagainstNK-sensitive
targets than CD5-/3.2.3 (bright+) cells and were not observed in normal F344 rats.
Theymay represent either pre-NK cells, which appear inthe spleens ofrats depleted
ofactive NK cells due to an unknown regulatory mechanism, or mature NK cells
with decreased cytolytic function due to in vivo binding of3.2.3, possibly leading
to receptor modulation and functional impairment.
In addition to depletion ofNK/ADCC activity, almost no LGLcouldbe detected
in Giemsa-stained cytospins of spleen cells or PBMC from 3.2.3-treated rats. The
few remaining LGL after mAb 3.2.3 treatment were morphologically distinct from
LGL observedin cytospin preparations from untreated rats. Thesecells were smaller
in size and contained fewer and smallergranules (data not shown). Thesecells could
either represent CD5-/3.2.3(dim+) NK cells (as suggested above) or the CD5+/
3.2.3(dim+) Tcells. Additional studies are currently in progress todetermine these
two possibilities.
The selective depletion of NK cells with mAb 3.2.3 resulted in a decreased sur-
vival afterintravenous injection ofMADB106 mammary adenocarcinoma cells. How-
ever, depletion of NK cells did not appear to influence the growth of MADB106
cells injected subcutaneously. Our findings with the growth ofMADB106 intrave-
nously or subcutaneously in NK-depleted animalssupport the resultsofother inves-
tigators that(a) NKcellsare involved in theeliminationoftumorcellsinvivo (12-15),
and(b) NKcells in vivo arelesseffective against subcutaneous growing tumors than
against tumor metastases in visceral organs (22).
In the past, various antibodies have been used to deplete NK cells in vivo. The
first antiserum to be used for in vivo treatment of mice and rats was anti-asialoVAN DEN BRINK ET AL.
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GMi . This is a rabbit antiserum that recognizes a glycosphingolipid, ganglio-
N-tetraosylceramide (23) present on mouse (23, 24), rat (25), and human (7) NK
cells. However, asialo GM, is not a specific marker for NK cells, since it has been
found to be expressed on interstitial and alveolar lung macrophages (26, 27), acti-
vated peritoneal macrophages (28, 29), alloimmune cytotoxic T lymphocytes (30),
peripheral blood T cells (25), and subpopulations ofcells in thymus, bone marrow,
and lymph nodes (31, 32).
Treatment ofmice or rats invivo with anti-asialo GM, antisera can provide effec-
tive depletion ofNK activity without significantly affecting the function ofT and
B lymphocytes (33, 34). However, this is highly dosage dependent and high levels
of anti-asialo GM, can also inhibit T cell functions (15). Habu et al. (33) showed
that in anti-asialo GMi-treated nude mice the incidence oftumor take as well as
tumor growth were enhanced when syngeneic (RLm-1), allogeneic (YAC-1), and
human tumors were transplanted subcutaneously. Goreliket al. (22) found that sup-
pression ofNK activity with anti-asialo GM, did not influence the growth oflocal
tumors inC57BL/6mice inoculated in thefootpadwithB16melanoma or 3LLtumor
cells, but accelerated thedevelopment of spontaneous pulmonary metastases. Also,
the number of metastatic foci in the lungs of anti-asialo GMi-treated C57BL/6
mice increased 10 times after intravenous inoculation with B16 melanoma. Similar
results have been observed by several other investigators (21, 35-38) .
In addition to anti-asialo GMi, an NK-specific alloantiserum, anti-NK-1.1, can
also be used to deplete mouse NK activity. Pollack and Hallenbeck (39) observed
a reduced tumor clearancein lungs, liver, and spleen aftertreatment with anti-NK1.1.
Finally, the mAb OX8 (anti-C138), which recognizes cytotoxic/suppressor T cells,
thymocytes, as well as NK cells in the rat, has been used in NK depletion studies
(40, 41). However, the disadvantages ofusingthis mAb fordepletion studies are ob-
vious, sinceOX8 cannot distinguish cytotoxic/suppressor T cells from NKcells, and
therefore, it does not allow a selective depletion of NK cells. Moreover, OX8 does
not provide complete depression of NK activity in vivo (40, 41).
The use ofmAb 3.2.3 for in vivo NK depletion in rats is preferable to anti-asialo
GMy or OX8 because of its strong and long-lasting effect and its high selectivity
for NK cells. So far we have obtained complete NK depletion in various rat strains
including Fischer 344, ACI, and Lewis (data not shown), suggesting that the NK
depletionwith mAb 3.2.3 is not strain dependent. We believe, therefore, that in vivo
treatment of rats with mAb 3.2.3 will be useful for studies on the functional role
of NK cells in vivo, as well as their growth and differentiation from 3.2.3- pre-
cursors.
Summary
We recently described amAb3.2.3 (IgGI), that recognizes a 60-kD dimeric mole-
cule expressed exclusively on fresh and rIL-2-activated NK cells and polymor-
phonuclear cells(16). mAb3.2.3enhances cytolyticactivity ofNKcellsagainst selected
FcR+ tumor target cells by reverse antibody-dependent cellular cytotoxicity
(ADCC), indicating that it recognizes animportanttriggering site on NKcells. The
invivotreatmentofF344ratswith mAb 3.2.3intraperitoneallycompletely and selec-
tively eliminated NK/ADCC function in the spleen and peripheral blood for up to
10daftertreatment. Totalnumbers and percentages ofT cells, monocytes, orPMN208
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were not decreased and T cell function, as determined by Con A stimulation, was
not affected. The reduction in NK function was associated with a decrease in the
numbers of LGL and the expression of other NK-related cell surface markers in-
cluding CD2, CD8, and asialo GM, . Depletion of NK cells with 3.2.3 markedly
decreased the survival of F344 rats injected intravenously with MADB106 mam-
mary adenocarcinoma cells, but did not affect the subcutaneous growth ofMADB106
tumors. These results indicate that mAb 3.2.3 (in contrast to anti-asialo GM, and
OX8, which are less selective markers) will be useful for studies on the functional
role of NK cells in vivo as well as their in vivo differentiation and origin from 3.2 .3 -
precursors.
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